Peripheral Blood CD19+CD27- Naïve B Cells, Frozen

Human CD19+CD27– naïve B cells are isolated from peripheral blood mononuclear cells by means of negative selection. Cells expressing CD2, CD14, CD16, CD27, CD36, CD43, and CD235a are depleted from the mononuclear cell population using immunomagnetic particles leaving purified, untouched CD19+CD27– naïve B cells. Isolated cells are characterized by flow cytometry before cryopreservation to ensure a highly pure and viable cell population.

Cells were obtained using Institutional Review Board (IRB) approved consent forms and protocols.

Since our founding in 2010, CGT Global has pursued our mission to transform healthcare as we accelerate cell and gene therapy research and clinical trials, streamline the commercialization of new treatments, and map the last mile to patient access to these life-changing remedies.  By innovating each stage in the cycle; development, commercialization, and delivery, we reduce the overall cost of the care and multiply access points so that millions can receive cutting edge, life-saving gene and cell therapies.

CGT Global - Landing Page Desktop Prototype

Description

Peripheral blood CD19+CD27- naïve B cells are B cells that have not encountered an antigen. Upon antigen contact naïve B cells will undergo isotype class-switch recombination and somatic hypermutation and develop into plasma and memory B cells.

Additional information

Anticoagulant

Format

Grade

Species

Cell and Tissue Source

Disease State

Donor Attributes

Product Information Sheet

 

Figure 1. Representative flow data of peripheral blood enriched CD19+CD27 naive B cells prior to cryopreservation.